

DAFTAR PUSTAKA

- Cheng S, Jie-Jen Lee, Ming-Nan Chien, Chi-Yu Kuo, Jie-Yang Jhuang, Chien-Liang Liu, Lymphovascular invasion of papillary thyroid carcinoma revisited in the era of active surveillance, *European Journal of Surgical Oncology*, Volume 46, Issue 10, Part A, 2020 1814-1819.
<https://doi.org/10.1016/j.ejso.2020.06.044>.
- Chiapponi C, Alakus H, Schmidt M, Faust M, Bruns CJ, Büttner R, Eich M-L and Schultheis AM (2022) Lymphatic Vessel Invasion in Routine Pathology Reports of Papillary Thyroid Cancer. *Front. Med.* 9:841550. doi: 10.3389/fmed.2022.841550
- Ethier JL, Desautels D, Templeton A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and metaanalysis. *Breast Cancer Res* 2017;19:2.
- Feng J, Wang Y, Shan G, Gao L. Clinical and prognostic value of neutrophil-to-lymphocyte ratio for patients with thyroid cancer: a metaanalysis. *Medicine* 2020;99:20(e19686).
- Gambardella C, Tartaglia E, Nunziata A, Izzo G, Siciliano G, Cavallo F, et al. Clinical significance of prophylactic central compartment neck dissection in the treatment of clinically node-negative papillary thyroid cancer patients. *World J Surg Oncol* 2016;14(1):247.
<https://doi.org/10.1186/s12957-016-1003-5>.
- Lee YJ, Huh JW, Shin JK, Park YA, Cho YB, Kim HC, et al. Risk factors for lymph node metastasis in early colon cancer. *Int J Colorectal Dis.* (2020) 35:1607–13. doi: 10.1007/s00384-020-03618-7
- Liu G, Ke LC, Sun SR. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in patients with soft tissue sarcoma. *Medicine* 2018;97: e12176.
- Liu, C.-L.; Lee, J.-J.; Liu, T.-P.; Chang, Y.-C.; Hsu, Y.-C.; Cheng, S.-P. Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer. *J. Surg. Oncol.* 2013, 107, 493–497.

Liu, JF., Ba, L., Lv, H. *et al.* Association between neutrophil-to-lymphocyte ratio and differentiated thyroid cancer: a meta-analysis. *Sci Rep* 6, 38551 (2016). <https://doi.org/10.1038/srep38551>

Luo XF, Zhou LH. Prognostic significance of neutrophil to lymphocyte ratio in patients with gastrointestinal stromal tumors: a meta-analysis. *Clin Chim Acta* 2018;477:7–12.

Manatakis, D.K.; Tseleni-Balafouta, S.; Balalis, D.; Soulou, V.N.; Korkolis, D.P.; Sakorafas, G.H.; Plataniotis, G.; Gontikakis, E. Association of Baseline Neutrophil-to-Lymphocyte Ratio with Clinicopathological Characteristics of Papillary Thyroid Carcinoma. *Int. J. Endocrinol.* 2017, 2017, 1–7.

Mete O, Asa SL. Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. *Mod Pathol* 2011;24(12):1545-52.
<https://doi.org/10.1038/modpathol.2011.119>.

Oguma J, Ozawa S, Kazuno A, Yamamoto M, Ninomiya Y, Yatabe K, Makuuchi H, Ogura G. Prognostic impact of lymphovascular invasion in lymph node-negative superficial esophageal squamous cell carcinoma. *Dis Esophagus*. (2019) 32:doz001. doi: 10.1093/dote/doz001

Qu H, Sun Gr, Liu Y, He Qs. Clinical risk factors for central lymph node metastasis in papillary thyroid carcinoma: A systematic review and meta-analysis. *Clin Endocrinol* 2015;83(1):124-32.
<https://doi.org/10.1111/cen.12583>.

Sezer A, Celik M, Yilmaz Bulbul B, Can N, Tastekin E, Ayturk S, Ustun F, Guldiken S, Sut N. Relationship between lymphovascular invasion and clinicopathological features of papillary thyroid carcinoma. *Bosn J Basic Med Sci.* 2017 May 20;17(2):144-151. doi: 10.17305/bjbm.2017.1924.

Sun Y, Zhang L. The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis. *Cancer Manag Res* 2018;10:6167–79.

Wagner K, Abraham E, Tran B, Roshan D, Wykes J, Campbell P, Ebrahimi A. Lymphovascular invasion and risk of recurrence in papillary thyroid

10.1111/ans.16202. Epub 2020 Aug 5. PMID: 32761711.

- Wakayama A, Kudaka W, Matsumoto H, Aoyama H, Ooyama T, Taira Y, et al. Lymphatic vessel involvement is predictive for lymph node metastasis and an important prognostic factor in endometrial cancer. *Int J Clin Oncol*. (2018) 23:532–8. doi: 10.1007/s10147-017-1227-6
- Wu J, Chen M, Liang C, et al. Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in cervical cancer: a meta-analysis and systematic review. *Oncotarget* 2017;8:13400–12
- Abdullah, M. I., Junit, S. M., Ng, K. L., Jayapalan, J. J., Karikalan, B., & Hashim, O. H. 2019. Papillary thyroid cancer: Genetic alterations and molecular biomarker investigations. *International Journal of Medical Sciences*, 16(3), 450–460. <https://doi.org/10.7150/ijms.29935>
- Allen, E., & Fingeret, A. 2021. *Anatomy, Head and Neck, Thyroid*. StatPearls Publishing.
- Arrangoiz, R., Cordera, F., Caba, D., Muñoz, M., Moreno, E., & de León, E. L. 2018. Comprehensive Review of Thyroid Embryology, Anatomy, Histology, and Physiology for Surgeons. *International Journal of Otolaryngology and Head & Neck Surgery*, 07(04), 160–188. <https://doi.org/10.4236/ijohns.2018.74019>
- Benvenga, S., Tuccari, G., Ieni, A., & Vita, R. 2018. Thyroid gland: Anatomy and physiology. In *Encyclopedia of Endocrine Diseases* (2nd ed.). Elsevier Inc. <https://doi.org/10.1016/B978-0-12-801238-3.96022-7>
- Cabanillas, M. E., McFadden, D. G., & Durante, C. 2016. Thyroid cancer. *The Lancet*, 388(10061), 2783–2795. [https://doi.org/10.1016/S0140-6736\(16\)30172-6](https://doi.org/10.1016/S0140-6736(16)30172-6)
- Carling, T., & Udelsman, R. 2014. Thyroid cancer. *Annual Review of Medicine*, 65(October), 125–137. <https://doi.org/10.1146/annurev-med-061512-105739>
- Chae, I. H., Kim, E.-K., Moon, H. J., Yoon, J. H., Park, V. Y., Lee, H. S., Moon, J., & Kwak, J. Y. 2018. Preoperative High Neutrophil-Lymphocyte Ratio May Be Associated with Lateral Lymph Node Metastasis in Patients with Papillary Thyroid Cancers. *International Journal of Thyroidology*, 11(1), 41.

- Filetti, S., Durante, C., Hartl, D., Leboulleux, S., Locati, L. D., Newbold, K., Papotti, M. G., & Berruti, A. 2019. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, 30(12), 1856–1883. <https://doi.org/10.1093/annonc/mdz400>
- Filetti, S., Durante, C., Hartl, D., Leboulleux, S., Locati, L. D., Newbold, K., Papotti, M. G., Berruti, A., & Committee, G. 2019. Thyroid cancer : ESMO Clinical Practice Guidelines for diagnosis , treatment and follow-up. *Cancer-Related Cognitive Impairment*, 30(12), 1856–1883. <https://doi.org/10.1093/annonc/mdz400>
- Gong, W., Yang, S., Yang, X., & Guo, F. 2016. Blood preoperative neutrophil-to-lymphocyte ratio is correlated with TNM stage in patients with papillary thyroid cancer. *Clinics*, 71(6), 311–314. [https://doi.org/10.6061/clinics/2016\(06\)04](https://doi.org/10.6061/clinics/2016(06)04)
- Gonzalez-Gonzalez, R., Bologna-Molina, R., Carreon-Burciaga, R. G., Gómezpalacio-Gastelum, M., Molina-Frechero, N., & Salazar-Rodríguez, S. 2011. Papillary Thyroid Carcinoma: Differential Diagnosis and Prognostic Values of Its Different Variants: Review of the Literature. *ISRN Oncology*, 2011(December), 1–9. <https://doi.org/10.5402/2011/915925>
- Haddad, R. I., Nasr, C., Bischoff, L., Busaidy, N. L., Byrd, D., Callender, G., Dickson, P., Duh, Q. Y., Ehya, H., Goldner, W., Haymart, M., Hoh, C., Hunt, J. P., Iagaru, A., Kandeel, F., Kopp, P., Lamonica, D. M., McIver, B., Raeburn, C. D., ... Gurski, L. A. 2018. NCCN Guidelines Insights : Thyroid Carcinoma. *JNCCN Journal of the National Comprehensive Cancer Network*, 16(12), 1429–1440. <https://doi.org/10.6004/jnccn.2018.0089>
- Kim, J. Y., Park, T., Jeong, S. H., Jeong, C. Y., Ju, Y. T., Lee, Y. J., Hong, S. C., Ha, W. S., Choi, S. K., & Jung, E. J. 2014. Prognostic importance of baseline neutrophil to lymphocyte ratio in patients with advanced papillary thyroid carcinomas. *Endocrine*, 46(3), 526–531. <https://doi.org/10.1007/s12020-013-0089-6>
- Kim, S. M., Kim, E. H., Kim, B. H., Kim, J. H., Park, S. Bin, Nam, Y. J., Ahn, K. H., Oh, M. Y., Kim, W. J., Jeon, Y. K., Kim, S. S., Kim, Y. K., & Kim, I. J.

2015. Association of the preoperative neutrophil-to-lymphocyte count ratio and platelet-to-lymphocyte count ratio with clinicopathological characteristics in patients with papillary thyroid cancer. *Endocrinology and Metabolism*, 30(4), 494–501. <https://doi.org/10.3803/EnM.2015.30.4.494>
- Kim, W. B. 2015. A closer look at papillary thyroid carcinoma. *Endocrinology and Metabolism*, 30(1), 1–6. <https://doi.org/10.3803/EnM.2015.30.1.1>
- Lee, E., Jung, W., Woo, J. S., Lee, J. B., Shin, B. K., Kim, H. K., Kim, A., & Kim, B. H. 2014. Tumor sprouting in papillary thyroid carcinoma is correlated with lymph node metastasis and recurrence. *Korean Journal of Pathology*, 48(2), 117–125. <https://doi.org/10.4132/KoreanJPathol.2014.48.2.117>
- Liu, X., Huang, Z., He, X., Zheng, X., Jia, Q., Tan, J., Fan, Y., Lou, C., & Meng, Z. 2020. Blood prognostic predictors of treatment response for patients with papillary thyroid cancer. *Bioscience Reports*, 40(10), 1–10. <https://doi.org/10.1042/BSR20202544>
- Marques, P., De Vries, F., Dekkers, O. M., Korbonits, M., Biermasz, N. R., & Pereira, A. M. 2021. Serum Inflammation-based Scores in Endocrine Tumors. *Journal of Clinical Endocrinology and Metabolism*, 106(10), E3796–E3819. <https://doi.org/10.1210/clinem/dgab238>
- Metere, A., Aceti, V., & Giacomelli, L. 2019. The surgical management of locally advanced well-differentiated thyroid carcinoma : changes over the years according to the AJCC 8th edition Cancer Staging Manual. *Thyroid Research*, 2019, 1–7.
- Offi, C., Romano, R. M., Cangiano, A., Candela, G., & Docimo, G. 2021. Clinical significance of neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, platelet-to-lymphocyte ratio and prognostic nutritional index in low-risk differentiated thyroid carcinoma. *Acta Otorhinolaryngologica Italica*, 41(1), 31–38. <https://doi.org/10.14639/0392-100X-N1089>
- Pontius, L. N., Youngwirth, L. M., Thomas, S. M., Randall P. Scheri, Roman, S. A., & Sosa, J. A. 2015. Lymphovascular Invasion is Associated with Survival for Papillary Thyroid Cancer. *Endocr Relat Cancer*, 412, 1–21.
- Sezer, A., Celik, M., Bulbul, B. Y., Can, N., Tastekin, E., Ayturk, S., Ustun, F.,

and clinicopathological features of papillary thyroid carcinoma. *Bosnian*

Journal of Basic Medical Sciences, 17(2), 144–151.

<https://doi.org/10.17305/bjbms.2017.1924>

Shah, J. P. 2017. HHS Public Access. *Clin Adv Hematol Oncol*, 13(4), 3–6.

Sherwood, L. 2001. *Fisiologi Manusia dari Sel ke Sistem* (B. I. Santoso (ed.); 2nd ed.). EGC.

The Global Cancer Observatory. 2020. Cancer Incident in Indonesia.

International Agency for Research on Cancer, 858, 1–2. <https://gco.iarc.fr/>

Tortora, G. J., & Derrickson, B. 2012. *Principles of Anatomy & Physiology* (13th ed.). Wiley.

Tuttle, R. M., Tala, H., Shah, J., Leboeuf, R., Ghossein, R., Gonen, M., Brokhin, M., Omry, G., & Fagin, J. A. 2010. Estimating Risk of Recurrence in Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation : Using Response to Therapy Variables to Modify the Initial Risk Estimates Predicted by the New American Thyroid Association S. *Thyroid*, 20(12), 1341–1349.

<https://doi.org/10.1089/thy.2010.0178>

Wagner, K., Abraham, E., Tran, B., Roshan, D., Wykes, J., Campbell, P., & Ebrahimi, A. 2020. Lymphovascular invasion and risk of recurrence in papillary thyroid carcinoma. *ANZ Journal of Surgery*, 90(9), 1727–1732.

<https://doi.org/10.1111/ans.16202>



UNIVERSITAS
GADJAH MADA

**Pengaruh Lymphovascular Invasion (LVI) dan Neutrophil-Lymphocyte Ratio (NLR) Terhadap
Rekurensi
Locoregional dan Progression Free Survival (PFS) pada Pasien Papillary Thyroid Carcinoma di RSUP
Dr.
Sardjito Pada Periode 2016-2020**

Davega Andratama, dr. Herjuna Hardiyanto, Sp.B(K)Onk;Dr. Sumadi Lukman Anwar, M.Sc, Ph.D., SpB (K) Onk
Universitas Gadjah Mada, 2023 | Diunduh dari <http://etd.repository.ugm.ac.id/>